Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Tenax Therapeutics' 2026 annual meeting of stockholders held on June 2, 2026. The filing presents voting results for two proposals: (1) election of seven directors to one-year terms, with vote tallies for each nominee (For/Withheld/Broker Non-Votes), and (2) ratification of Cherry Bekaert LLP as independent auditor. The disclosure is material as it documents the outcome of shareholder governance actions and confirms the composition of the board and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
CV Sciences held its 2026 Annual Meeting on June 2, 2026, with shareholders voting on three proposals: election of three directors (passed), authorization of a reverse stock split (failed), and ratification of Haskell & White LLP as independent auditor (passed). The filing reports final voting tallies including vote counts, percentages, and broker non-votes.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder vote results from the 2026 annual meeting held on June 2, 2026, covering three matters: election of nine directors, ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of executive compensation. The filing presents vote tallies (for, against, withheld, abstain, broker non-votes) for each matter, which is the standard format for Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
OnKure held its Annual Meeting of Stockholders on June 3, 2026, with shareholders voting on three proposals: election of Class II directors (Carruthers, Jansen, Mathers), ratification of KPMG LLP as independent auditor, and approval of the Amended and Restated 2024 Equity Incentive Plan. Vote results for all three proposals are disclosed with detailed tallies.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of MasterBrand's Annual Meeting of Shareholders held on June 4, 2026. The filing presents voting results for three proposals: election of three directors (Ann Fritz Hackett, R. David Banyard, Jr., and Philip Fracassa), advisory approval of 2025 NEO compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. All three proposals passed with substantial majorities. Shareholder vote results are material to investors as they reflect governance outcomes and stakeholder approval of key corporate matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder vote results from Royalty Pharma's 2026 Annual General Meeting held on June 4, 2026. The filing presents detailed vote tabulations for all 10 proposals submitted to shareholders, including director elections, executive compensation approval, auditor ratification, and share authorization matters. Item 5.07 is the designated 8-K item for shareholder vote results, and the prose directly reports the inspector of election's certified vote counts for each proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
Sarepta held its Annual Meeting of Stockholders on June 4, 2026, with stockholders voting on five proposals: election of five Class I directors (Douglas S. Ingram, Hans Wigzell, Kathryn J. Boor, Michael Chambers, and Deirdre Connelly), advisory approval of named executive officer compensation, approval of the 2026 Equity Incentive Plan, approval of the 2026 Employee Stock Purchase Plan, and ratification of KPMG as independent auditor. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
Kaiser Aluminum held its 2026 Annual Meeting of Stockholders, with results including election of three Class I directors (Hoffman, Minor, Wilcox), advisory approval of named executive officer compensation (98.68% for), ratification of Deloitte & Touche LLP as independent auditor (98.20% for), and approval of the Amended 2021 Equity and Incentive Compensation Plan increasing available shares by 395,000 (94.43% for).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
CRISPR Therapeutics held its Annual Meeting on June 4, 2026, and disclosed the final voting results for 13 proposals, including approval of financial statements, board re-elections, compensation approvals, capital increases, and auditor re-elections, with detailed tabulation of votes cast for each proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from LifeStance Health Group's June 2, 2026 annual meeting. The filing reports voting outcomes for three proposals: election of directors (Proposal 1), ratification of PricewaterhouseCoopers LLP as independent auditor (Proposal 2), and advisory vote on named executive officer compensation (Proposal 3), with detailed vote tallies for each. This is a material disclosure as it documents stockholder approval of key governance matters including board composition and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a Form 8-K Item 5.07 disclosure of shareholder meeting results. The filing reports the final voting outcomes for three proposals at the June 4, 2026 annual meeting: election of two Class II directors (Malte Peters, M.D. and Mace Rothenberg, M.D.), ratification of PricewaterhouseCoopers, LLP as independent auditor, and advisory approval of named executive officer compensation. The disclosure includes vote tallies, quorum confirmation (90.96% attendance), and context regarding a prior director resignation. This is a material event as it reflects stockholder decisions on board composition and corporate governance matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This Item 5.07 disclosure presents the tabulated results of stockholder votes at Arteris's June 2, 2026 Annual Meeting of Stockholders on two proposals: election of three Class II directors and ratification of Deloitte & Touche, LLP as the independent auditor for fiscal 2026. The filing provides vote counts (For, Against/Withheld, Abstentions, and Broker Non-Votes) for each proposal, which is the standard format for shareholder vote result disclosures required under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from Kodiak Sciences' June 2, 2026 Annual Meeting of Stockholders. The filing presents voting outcomes for three proposals: election of Class II directors (Bancroft, Dahiyat, and Yang), advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. All three proposals passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely upon to assess board composition and executive accountability.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder vote results from LeMaitre Vascular's June 2, 2026 Annual Meeting of Stockholders. The filing reports voting outcomes on three proposals: election of two Class II directors (David B. Roberts and John A. Roush), advisory approval of executive compensation, and ratification of Grant Thornton LLP as independent auditor. All three proposals passed by majority vote. This is a routine but material disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder vote results from Power Integrations' 2026 Annual Meeting held on June 3, 2026. The filing reports voting outcomes on five proposals: director elections (Proposal One), advisory say-on-pay (Proposal Two), auditor ratification (Proposal Three), equity plan amendment (Proposal Four), and a governance proposal (Proposal Five). The detailed vote tallies and quorum information (96.45% attendance) are characteristic of Item 5.07 shareholder vote disclosures, which are material to investors assessing corporate governance and shareholder sentiment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This Item 5.07 filing discloses the results of Oruka Therapeutics' Annual Meeting of Stockholders held on June 2, 2026, with detailed vote tallies for three proposals: election of two Class II directors (Lawrence Klein and Chris Martin), ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents the complete voting results including shares voted for/against, abstentions, and broker non-votes for each matter, which is the core disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder vote results from LegalZoom's June 3, 2026 annual meeting under Item 5.07. The filing reports final voting tallies for three proposals: election of director Sivan Whiteley, ratification of PricewaterhouseCoopers LLP as auditor, and advisory vote on named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material governance disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
Pacific Biosciences held its Annual Meeting of Stockholders on June 3, 2026, with shareholders voting on four proposals: election of four Class III directors, ratification of Ernst & Young LLP as independent auditor, advisory vote on named executive officer compensation, and approval of an amendment to the 2020 Equity Incentive Plan reserving an additional 16,000,000 shares. Detailed vote tallies for each proposal were disclosed.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from the June 3, 2026 Annual Meeting of Stockholders. The filing presents certified voting tallies for three proposals: election of Class III directors (Proposal 1), advisory vote on named executive officer compensation (Proposal 2), and ratification of Baker Tilly US, LLP as independent auditor (Proposal 3). All three proposals were approved by stockholders, with detailed vote counts provided for each matter.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes for four proposals at Neurogene's June 3, 2026 Annual Meeting: election of two Class III directors (Robert Baffi and Rohan Palekar), advisory approval of named executive officer compensation, ratification of Deloitte & Touche LLP as auditor, and an advisory vote on the frequency of future compensation votes. The detailed vote tallies and quorum information are standard for this event type.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of LendingClub's June 2, 2026 annual meeting of stockholders. The filing presents voting outcomes for five proposals: election of three Class III directors (Kathryn Reimann, Scott Sanborn, Michael Zeisser), advisory vote on named executive officer compensation, ratification of Deloitte & Touche LLP as auditor, and two charter amendments (board declassification and removal of supermajority voting requirements). All proposals passed with substantial majorities. This is material as it confirms governance changes and director elections that affect the registrant's leadership and control structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of OrthoPediatrics Corp.'s 2026 Annual Meeting of Stockholders held on June 4, 2026. The filing presents voting results for four matters: election of four directors (with vote tallies for each nominee), advisory approval of named executive officer compensation, approval of a 2024 Incentive Award Plan amendment increasing authorized shares by 2,050,000, and approval of Deloitte & Touche LLP as independent auditor. All four proposals passed with substantial majorities. This is material as it documents the outcome of shareholder governance actions and confirms the composition of the board and key corporate decisions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
Stockholders voted at the June 2, 2026 Annual Meeting on four proposals: election of four directors (McCarthy, Bryant, Foster, Giovacchini), advisory approval of named executive officer compensation, approval of the Amended and Restated 2021 Omnibus Incentive Plan, and ratification of Deloitte & Touche as independent auditor. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
Ideal Power Inc. held its Annual Meeting on June 3, 2026, with shareholders voting on four proposals: election of five directors, ratification of auditor BPM LLP, advisory approval of named executive officer compensation, and approval of the Amended and Restated 2013 Equity Incentive Plan. All four proposals were approved by shareholders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder vote results from BAB, Inc.'s annual meeting held June 3, 2026, covering two proposals: election of four directors and ratification of CBIZ CPAs P.C. as independent auditors. The filing presents detailed voting tallies (votes for, against, withheld, abstentions, and broker non-votes) for each proposal, which is the quintessential content of Item 5.07 shareholder vote results disclosures and is material to investors assessing board composition and auditor selection.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Tucows Inc.'s Annual Meeting of Shareholders held on June 2, 2026. The filing presents voting results for three proposals: election of eight directors, non-binding advisory vote on named executive officer compensation, and ratification of Deloitte LLP as independent auditors. All proposals passed with substantial majorities, making this a material shareholder vote result disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This Item 5.07 filing discloses the results of three stockholder votes at Ormat Technologies' 2026 Annual Meeting: election of eight directors, advisory approval of named executive officer compensation, and ratification of the independent auditor. The detailed vote tallies (For, Against, Abstained, Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results. All three proposals passed with substantial majorities, making this a material governance event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
General Motors held its Annual Meeting of Shareholders on June 2, 2026, with voting results on seven proposals including election of 10 directors, ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, frequency of future advisory votes on NEO compensation, approval of Amendment No. 2 to the 2020 Long-Term Incentive Plan (increasing share availability by 27 million shares and extending the plan to 2036), and two shareholder proposals regarding separation of Chair/CEO roles and human rights standards reporting.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder voting results from Vita Coco's Annual Meeting of Stockholders held on June 3, 2026, covering three proposals: election of three Class II directors (Shelley Broader, Michael Kirban, and Kenneth Sadowsky), ratification of Deloitte & Touche LLP as independent auditor, and an advisory vote on executive compensation. The filing explicitly states the voting tallies and outcomes for each item, which is the hallmark of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-04
The filing discloses results of Lipocine's June 3, 2026 annual shareholder meeting under Item 5.07, including voting outcomes on director elections, auditor ratification, executive compensation advisory vote, and approval of the Sixth Amended and Restated 2014 Stock and Incentive Plan with increased share authorization (from 600,000 to 1,000,000 shares) and individual award limits (from 25,000 to 100,000). The shareholder approval of the expanded equity plan is material to investors assessing potential dilution and executive compensation arrangements.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
Upland Software held its Annual Meeting of Stockholders on June 3, 2026, with shareholders voting on six proposals including director elections, auditor ratification, executive compensation advisory vote, reverse stock split approval, equity plan share reserve increase, and adjournment. The reverse stock split and equity plan amendments were approved and represent material corporate actions affecting shareholder holdings and dilution.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders held on June 4, 2026. The filing reports voting outcomes for two matters: (1) election of directors Kim Kamdar, Ph.D. and Sandra A. J. Lawrence as Class II directors, and (2) ratification of Ernst & Young LLP as independent auditor. The detailed vote tallies (shares voted for, withheld, against, abstaining, and broker non-votes) are presented in tabular form, which is the standard format for Item 5.07 disclosures. Director elections and auditor ratification are material governance matters affecting investor confidence in board composition and financial oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder voting results from Aurinia's annual general meeting held June 3, 2026. The filing reports final voting tallies for three proposals: election of five board directors (Proposal 1), appointment of PricewaterhouseCoopers LLP as independent auditor (Proposal 2), and advisory approval of executive compensation (Proposal 3), with detailed vote counts and percentages for each. This is a quintessential Item 5.07 shareholder_vote_results event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a classic Item 5.07 disclosure of shareholder vote results from Vontier's Annual Meeting held June 4, 2026. The filing reports voting outcomes on three proposals: election of seven directors, ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material governance disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder vote results from a Special Meeting held on June 3, 2026, reporting voting outcomes on four proposals including approval of an asset sale to Allbirds IP LLC, a charter amendment, issuance of shares upon convertible note conversion, and an adjournment proposal. The asset sale approval is particularly material as it represents a significant disposition of company assets. Item 5.07 explicitly governs shareholder vote results, and the filing directly reports the vote tallies and outcomes for each proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
Lyft held its annual meeting of stockholders on June 3, 2026, with shareholders voting on six proposals: election of three directors (David Risher, Deborah Hersman, Dave Stephenson), ratification of PricewaterhouseCoopers LLP as auditor, advisory votes on executive compensation and frequency thereof, and two amendments to the Restated Certificate of Incorporation. All proposals passed.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
Globus Medical held its Annual Meeting of Stockholders and disclosed voting results on four proposals: election of two Class II directors (Keith W. Pfeil and Robert A. Douglas), approval of an amendment to the 2021 Equity Incentive Plan increasing authorized shares by 1,000,000, ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of 2025 named executive officer compensation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
iHeartMedia held its Annual Meeting on June 4, 2026, with shareholders voting on four proposals: election of eight directors, ratification of Ernst & Young LLP as auditor, advisory approval of named executive officer compensation, and approval of an amendment to the Long-Term Incentive Award Plan. All voting results were disclosed with detailed vote tallies.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder voting results from Figma's June 2, 2026 annual meeting of stockholders. The filing reports final vote tallies for two proposals: (1) election of eight directors, with detailed vote counts for each nominee, and (2) ratification of Ernst & Young LLP as independent auditor. This is a textbook Item 5.07 disclosure and is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder vote results from GoPro's June 2, 2026 Annual Meeting of Stockholders under Item 5.07. The filing reports voting outcomes on five proposals: election of seven directors, ratification of PricewaterhouseCoopers LLP as auditor, advisory vote on executive compensation, approval of 13 million additional shares under the 2024 Equity Incentive Plan, and approval of convertible debenture issuance under Nasdaq Rule 5635(d). All proposals passed with substantial majorities, and the disclosure includes detailed vote tallies for each nominee and proposal.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder voting results from Hinge Health's June 3, 2026 Annual Meeting of Stockholders. The filing reports final vote tallies for two proposals: (1) election of Class I directors Teddie Wardi and Tyler Sloat, and (2) ratification of Deloitte & Touche LLP as independent auditor. Both proposals passed with substantial majorities. This is a routine but material disclosure required under Item 5.07 of Form 8-K.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
BioMarin held its Annual Meeting of stockholders on June 4, 2026, with stockholders voting on four proposals: election of ten directors, ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2017 Equity Incentive Plan increasing the share reserve by 7,650,000 shares. All four proposals passed with detailed vote tallies disclosed.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder vote results from Axalta's June 3, 2026 Annual General Meeting. The filing reports voting outcomes on three matters: election of nine directors, appointment of PricewaterhouseCoopers LLP as auditor, and Say on Pay approval for 2025 named executive officers. The detailed vote tallies (votes for, against, withheld, abstentions, and broker non-votes) for each matter are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting results.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder vote results under Item 5.07. The filing reports the results of a special meeting held on June 4, 2026, where stockholders voted on a Reincorporation Proposal to convert the company from Delaware to Nevada incorporation. The vote tally shows 171,505,308 votes for (59.2%), 96,295,425 against (33.2%), and 147,411 abstentions, with the proposal approved. A reincorporation is a material corporate governance event affecting the registrant's legal structure and jurisdiction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
Abacus Global Management held its Annual Meeting on June 3, 2026, and disclosed voting results for five proposals: election of Class III directors (Jay Jackson and Thomas W. Corbett, Jr.), ratification of KPMG LLP as independent auditor, approval of the 2026 Long-Term Equity Incentive Plan, advisory vote on executive compensation, and advisory vote on Say-on-Pay frequency.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a classic Item 5.07 disclosure reporting the final voting results from Evolent Health's 2026 Annual Meeting of Stockholders held on June 4, 2026. The filing presents detailed vote tallies for four proposals: election of ten directors, ratification of Deloitte & Touche LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2015 Omnibus Incentive Compensation Plan. All proposals passed with substantial majorities, making this a material shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This Item 5.07 disclosure presents the final voting results from Rimini Street's June 3, 2026 Annual Meeting of Stockholders on three proposals: election of three Class III directors, a non-binding say-on-pay vote, and ratification of KPMG LLP as independent auditor. The tabulated vote counts for each proposal are the core content, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder vote results from TSS, Inc.'s annual meeting held on June 4, 2026. The filing reports final voting tallies for two proposals: (1) election of Class III directors (Peter Woodward and Vivek Mohindra) and (2) ratification of BDO USA, P.C. as independent auditor. This directly matches Item 5.07 and the shareholder_vote_results event type, which covers results of votes at annual or special meetings of security holders.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders held on June 4, 2026, filed under Item 5.07. The filing reports voting outcomes for three proposals: election of nine directors, advisory vote on executive compensation, and ratification of Deloitte LLP as independent auditor. All three proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition and shareholder approval of key corporate matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-04
Item 5.07
This is a clear disclosure of shareholder vote results from Bioventus's 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing reports voting outcomes for director elections (12 nominees) and ratification of Grant Thornton LLP as independent auditor, with detailed vote tallies (For, Withheld, Broker Non-Votes). This is the quintessential shareholder_vote_results event under Item 5.07, and is material as it documents the composition of the Board of Directors and auditor appointment.
View raw filing on EDGAR →